FDA authorized phase 1 trial of ImmunityBioﾒs novel COVID-19 vaccine candidate hAd5 to drive T cell and antibody immunity
On Oct. 15, 2020, ImmunityBio announced it had received authorization from the FDA to begin a Phase I…
-
-
FDA approved first treatment for Ebola virus
On Oct. 14, 2020, the FDA approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three…
-
US DOD expanded collaboration with AstraZeneca to develop and manufacture an investigational mab to prevent COVID-19
On Oct. 14, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD)…
-
Thermo Fisher Scientific expanded COVID-19 test portfolio with two new antibody tests
On Oct. 12, 2020, Thermo Fisher Scientific introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19…
-
NIAID clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
-
NIH clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
-
Emergent BioSolutionsﾒ COVID-19 product candidate included in NIH-sponsored phase 3 clinical trial
On Oct. 8, 2020, Emergent BioSolutions announced the initiation of the Phase 3 clinical trial that will evaluate…
-
Lilly announced supply of potential COVID-19 antibody therapy for low- and middle-income countries
On Oct. 8, 2020, Eli Lilly and the Bill & Melinda Gates Foundation, as part of the COVID-19…
-
Sorrento announced discovery of salicyn-30 small molecule that strongly inhibits SARS-CoV-2 infection
On Oct. 7, 2020, Sorrento Therapeutics announced that it had discovered a small molecule termed Salicyn-30 that demonstrated…
-
Lilly updated progress of SARS-CoV-2 neutralizing antibody programs
On Oct. 7, 2020, Eli Lilly announced additional details on its SARS-CoV-2 neutralizing antibody programs ﾖ including interim…
-
Sorrento Therapeutics and ViralClear entered agreement to explore combination antibody plus antiviral therapy against COVID-19
On Sept. 30, 2020, ViralClear Pharmaceuticals and Sorrento Therapeutics announced the companies were exploring the synergistic potential of…
-
FDA authorized first point-of-care antibody test for COVID-19
On Sept. 23, 2020, the FDA issued an emergency use authorization (EUA) for the first serology (antibody) point-of-care…
-
Oxford Immunotec joined with Public Health England in large clinical trial utilizing T-SPOT discovery SARS-CoV-2 test
On Sept. 22, 2020, Oxford Immunotec announced that it had entered into an extensive research collaboration with Public…
-
XBiotech to develop human antibody combination as candidate treatment for influenza-COVID-19 co-infection
On Sept. 21, 2020, XBiotech announced it was developing a new breakthrough candidate therapy it calls FLUVID for…
-
Roche launched new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines
On Sept. 18, 2020, Roche announced the launch of its Elecsys Anti-SARS-CoV-2 S antibody test for markets accepting…
-
Lilly and Amgen announced manufacturing collaboration for COVID-19 antibody therapies
On Sept. 17, 2020, Eli Lilly and Amgen announced a global antibody manufacturing collaboration to significantly increase the supply…
-
Lilly announced proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
On Sept. 16, 2020, Eli Lilly announced proof of concept data from an interim analysis of the BLAZE-1…
-
T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
On Sept. 16, 2020, a study by researchers at La Jolla Institute for Immunology published in the Cell,…
-
AXIM Biotechnologies filed Emergency Use Authorization with COVID-19 rapid diagnostic test for neutralizing antibodies
On Sept. 16, 2020, AXIM Biotechnologies announced that it had filed an Emergency Use Authorization (EUA) application with…
-
UTHealth joined NIH trial to test antibodies and other experimental outpatient treatments for COVID-19 pneumonia
On Sept. 15, 2020, the University of Texas Health Science Center at Houston (UTHealth) announced that a study…
-
RECOVERY COVID-19 phase 3 trial evaluated Regeneron’s REGN-COV2 investigational antibody cocktail in the UK
On Sept. 14, 2020, Regeneron and the University of Oxford announced that RECOVERY (Randomised Evaluation of COVid-19 thERapY),…
-
Meridian launched novel SARS-CoV-2 antibody pair designed for developing highly sensitive rapid antigen tests from saliva
On Sept. 14, 2020, Meridian Bioscience announced the launch of a novel highly sensitive SARS-CoV-2 antibody pair to…
-
MediciNova announced intranasal RS virus vaccine vuccessfully induced neutralizing antibodies against RS virus in mice
On Sept. 11, 2020, MediciNova announced that BioComo, co-developer of MediciNova’s SARS-CoV-2 vaccine for COVID-19, announced that its…
-
Corvus Pharmaceuticals provided update on clinical trial of CPI-006 for patients with COVID-19
On Sept. 10, 2020, Corvus Pharmaceuticals announced updated data from its ongoing Phase 1 study investigating the potential…
-
ADMA Biologics launched COVID-19 ImmunoRank Neutralization MICRO-ELISA for detection of SARS-CoV-2
On Sept. 3, 2020, ADMA Biologics announced the launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA…
-
Titers of antibodies against SARS-CoV2 did not decline within four months
On Sept. 1, 2020, scientists at deCODE genetics in Iceland, a subsidiary of Amgen, published a study in…
-
Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19
On Aug. 25, 2020, AstraZeneca announced that the first participants have been dosed in a Phase I trial…
-
AXIM Biotechnologies signed exclusive licensing, manufacturing and distribution agreement for production of COVID-19 rapid neutralizing antibody test
On Aug. 24, 2020, AXIM Biotechnologies announced that it had signed an exclusive limited licensing, manufacturing and distribution…
-
Biotechnology | COVID-19 | FDA | Therapeutics
XBiotech announced COVID-19 candidate therapy
On Aug. 24, 2020, XBiotech announced that the U.S. Food and Drug Administration (FDA) issued an emergency use…
-
La Jolla Institute for Immunology awarded $6.4 million for international efforts to beat COVID-19
On Aug. 20, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes…
